Cyclopentenone eicosanoids as mediators of neurodegeneration: A pathogenic mechanism of oxidative stress-mediated and cyclooxygenase-mediated neurotoxicity

Brain Pathology

Volumn 15, Issue 2, 2005, Pages 149-158

  Musiek, Erik S ^a   Milne, Ginger L ^a   McLaughlin, BethAnn ^a,b   Morrow, Jason D ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPENTENONE; DOCOSAHEXAENOIC ACID; ICOSANOID; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE;

ANTIINFLAMMATORY ACTIVITY; BRAIN; CHEMICAL STRUCTURE; CONFERENCE PAPER; DEGENERATIVE DISEASE; ENZYME ACTIVATION; MICROGLIA; NERVE CELL; NERVE DEGENERATION; NEUROPROTECTION; NEUROTOXICITY; OXIDATION; OXIDATIVE STRESS; PROTEIN EXPRESSION;

EID: 17444386729     PISSN: 10156305     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1750-3639.2005.tb00512.x     Document Type: Conference Paper

References (142)

1. Abdel-Halim MS, Lunden I, Cseh G, Anggard E (1980) Prostaglandin profiles in nervous tissue and blood vessels of the brain of various animals. Prostaglandins 19:249-258.
2. Akbar M, Kim HY (2002) Protective effects of docosahexaenoic acid in staurosporine-induced apoptosis: involvement of phosphatidylinositol-3 kinase pathway. J Neurochem 82:655-665.
3. Akiyama H, McGeer PL (2004) Specificity of mechanisms for plaque removal after A beta immunotherapy for Alzheimer disease. Nat Med 10:117-118.
4. Alvarez-Maqueda M, El Bekay R, Alba G, Monteseirin J, Chacon P, Vega A, Martin-Nieto J, Bedoya FJ, Pintado E, Sobrino F (2004) 15-deoxy-delta 12,14-prostaglandin J2 induces heme oxygenase-1 gene expression in a reactive oxygen species-dependent manner in human lymphocytes. J Biol Chem 279:21929-1937.
5. Aoun P, Watson DG, Simpkins JW (2003) Neuroprotective effects of PPARg agonists against oxidative insults in HT-22 cells. Eur J Pharmacol 472:65-71.
6. Atsmon J, Freeman ML, Meredith MJ, Sweetman BJ, Roberts LJ (1990) Conjugation of 9-deoxy-delta-9-delta 12-(E)-prostaglandin D2 with intracellular glutathione and enhancement of its anti-proliferative activity by glutathione depletion. Cancer Res 50:1879-1885.
7. Atsmon J, Sweetman BJ, Baertschi SW, Harris TM, Roberts LJ, 2nd (1990) Formation of thiol conjugates of 9-deoxy-delta 9,delta 12(E)-prostaglandin D2 and delta 12(E)-prostaglandin D2. Biochemistry 29:3760-3765.
8. Bayir H, Kagan VE, Tyurina YY, Tyurin V, Ruppel RA, Adelson PD, Graham SH, Janesko K, Clark RS, Kochanek PM (2002) Assessment of antioxidant reserves and oxidative stress in cerebrospinal fluid after severe traumatic brain injury in infants and children. Pediatric Res 51:571-578.
9. Beal MF (1995) Aging, energy, and oxidative stress in neurodegenerative diseases. Ann Neurol 38:357-66.
10. Bell-Parikh LC, Ide T, Lawson JA, McNamara P, Reilly M, FitzGerald GA (2003) Biosynthesis of 15-deoxy-delta12,14-PGJ2 and the ligation of PPARγ. J Clin Invest 112:945-955.
11. Bogaards JJ, Venekamp JC, van Bladeren PJ (1997) Stereoselective conjugation of prostaglandin A2 and prostaglandin J2 with glutathione, catalyzed by the human glutathione S-transferases A1-1, A2-2, M1a-1a, and P1-1. Chem Res Toxicol 10:310-317.
12. Bruckner SR, Perry G, Estus S (2003) 4-hydroxynonenal contributes to NGF withdrawal-induced neuronal apoptosis. J Neurochem 85:999-1005.
13. Calon F, Lim GP, Yang F, Morihara T, Teter B, Ubeda O, Rostaing P, Triller A, Salem N, Jr., Ashe KH, Frautschy SA, Cole GM (2004) Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. Neuron 43:633-645.
14. Castano A, Herrera AJ, Cano J, Machado A (2002) The degenerative effect of a single intranigral injection of LPS on the dopaminergic system is prevented by dexamethasone, and not mimicked by rh-TNF-alpha, IL-1beta and IFN-gamma. J Neurochem 81:150-157.
15. Castrillo A, Traves PG, Martin-Sanz P, Parkinson S, Parker PJ, Bosca L (2003) Potentiation of protein kinase C zeta activity by 15-deoxy-delta(12,14)- prostaglandin J(2) induces an imbalance between mitogen-activated protein kinases and NF-kappa B that promotes apoptosis in macrophages. Mol Cell Biol 23:1196-1208.
16. Cernuda-Morollon E, Pineda-Molina E, Canada FJ, Perez-Sala D (2001) 15-Deoxy-Delta 12,14-prostaglandin J2 inhibition of NF-kappaB-DNA binding through covalent modification of the p50 subunit. J Biol Chem 276:35530-35536.
17. Chawla A, Barak Y, Nagy L, Liao D, Tontonoz P, Evans RM (2001) PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med 7:48-52.
18. Chen H, Zhang SM, Hernan MA, Schwarzschild MA, Willett WC, Colditz GA, Speizer FE, Ascherio A (2003) Nonsteroidal anti-inflammatory drugs and the risk of Parkinson Disease. Arch Neurol 60:1059-1064.
19. Chen Y, Morrow JD, Roberts LJ, 2nd (1999) Formation of reactive cyclopentenone compounds in vivo as products of the isoprostane pathway. J Biol Chem 274:10863-10868.
20. Chen Y, Zackert WE, Roberts LJ, 2nd, Morrow JD (1999) Evidence for the formation of a novel cyclopentenone isoprostane, 15-A2t-isoprostane (8-iso-prostaglandin A2) in vivo. Biochim Biophys Acta 1436:550-556.
21. Chiarugi A (2002) Characterization of the molecular events following impairment of NF-kappaB-driven transcription in neurons. Brain Res Mol Brain Res 109:179-188.
22. Clay CE, Monjazeb A, Thorburn J, Chilton FH, High KP (2002) 15-Deoxy-delta12,14-prostaglandin J2-induced apoptosis does not require PPARγ in breast cancer cells. J Lipid Res 43:1818-1828.
23. Culmsee C, Siewe J, Junker V, Retiounskaia M, Schwarz S, Camandola S, El-Metainy S, Behnke H, Mattson MP, Krieglstein J (2003) Reciprocal inhibition of p53 and nuclear factor-kappaB transcriptional activities determines cell survival or death in neurons. J Neurosci 23:8586-8595.
24. de Bittencourt PI, Jr., Miyasaka CK, Curi R, Williams JF (1998) Effects of the antiproliferative cyclopentenone prostaglandin A1 on glutathione metabolism in human cancer cells in culture. Biochem Mol Biol Int 45:1255-1264.
25. Drachman DB, Frank K, Dykes-Hoberg M, Teismann P, Almer G, Przedborski S, Rothstein JD (2002) Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. Ann Neurol 52:771-778.
26. Du Y, Ma Z, Lin S, Dodel RC, Gao F, Bales KR, Triarhou LC, Chernet E, Perry KW, Nelson DL, Luecke S, Phebus LA, Bymaster FP, Paul SM (2001) Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci USA 98:14669-14674.
27. Fam SS, Murphey LJ, Terry ES, Zackert WE, Chen Y, Gao L, Pandalai S, Milne GL, Roberts LJ, Porter NA, Montine TJ, Morrow JD (2002) Formation of highly reactive A-ring and J-ring isoprostane-like compounds (A4/J4-neuroprostanes) in vivo from docosahexaenoic acid. J Biol Chem 277:36076-36084.
28. Feng ZH, Wang TG, Li DD, Fung P, Wilson BC, Liu B, Ali SF, Langenbach R, Hong JS (2002) Cyclooxygenase-2-deficient mice are resistant to 1-methy[-4-phenyl1, 2, 3, 6-tetrahydropyridine-induced damage of dopaminergic neurons in the substantia nigra. Neurosci Lett 329:354-358.
29. Fitzpatrick FA, Wynalda MA (1983) Albumin-catalyzed metabolism of prostaglandin D2. Identification of products formed in vitro. J Biol Chem 258:11713-11718.
30. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM (1995) 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 83:803-812.
31. Frolich JC, Sweetman BJ, Carr K, Hollifield JW, Oates JA (1975) Assessment of the levels of pga2 in human plasma by gas chromatography-mass spectrometry. Prostaglandins 10:185-195.
32. Fukushima M, Kato T, Ota K, Arai Y, Narumiya S, Hayaishi O (1982) 9-deoxy-delta 9-prostaglandin D2, a prostaglandin D2 derivative with potent antineoplastic and weak smooth muscle-contracting activities. Biochem Biophy Res Comm 109:626-633.
33. Gebicke-Haerter PJ (2001) Microglia in neurodegeneration: molecular aspects. Microsc Res Tech 54:47-58.
34. Graham SH, Hickey RW (2003) Cyclooxygenases in central nervous system diseases: a special role for cyclooxygenase 2 in neuronal cell death.(see comment)(comment). Arch Neurol 60:628-630.
35. Greco A, Minghetti L, Sette G, Fieschi C, Levi G (1999) Cerebrospinal fluid isoprostane shows oxidative stress in patients with multiple sclerosis. Neurology 53:1876-1879.
36. Hamberg M, Samuelsson B (1966) Prostaglandins in human seminal plasma. Prostaglandins and related factors 46. J Biol Chem 241:257-263.
37. Heneka MT, Feinstein DL, Galea E, Gleichmann M, Wullner U, Klockgether T (1999) Peroxisome proliferator-activated receptor gamma agonists protect cerebellar granule cells from cytokine-induced apoptotic cell death by inhibition of inducible nitric oxide synthase. J Neuroimmunology 100:156-168.
38. Heneka MT, Klockgether T, Feinstein DL (2000) Peroxisome proliferator-activated receptor-gamma ligands reduce neuronal inducible nitric oxide synthase expression and cell death in vivo. J Neurosci 20:6862-6867.
39. Hirata Y, Hayashi H, Ito S, Kikawa Y, Ishibashi M, Sudo M, Miyazaki H, Fukushima M, Narumiya S, Hayaishi O (1988) Occurrence of 9-deoxy-delta 9,delta 12-13,14-dihydroprostaglandin D2 in human urine. J Biol Chem 263:16619-16625.
40. Homem de Bittencourt PI, Jr., Curi R (2001) Antiproliferative prostaglandins and the MRP/GS-X pump role in cancer immunosuppression and insight into new strategies in cancer gene therapy. Biochem Pharmacol 62:811-819.
41. Honn KV, Marnett U (1985) Requirement of a reactive alpha, beta-unsaturated carbonyl for inhibition of tumor growth and induction of differentiation by "A" series prostaglandins. Biochem Biophys Res Comm 129:34-40.
42. Hortelano S, Castrillo A, Alvarez AM, Bosca L (2000) Contribution of cyclopentenone prostaglandins to the resolution of inflammation through the potentiation of apoptosis in activated macrophages. J Immunol 165:6525-6531.
43. Hubatsch I, Mannervik B, Gao L, Roberts U, Chen Y, Morrow JD (2002) The cyclopentenone product of lipid peroxidation, 15-A(2t)-isoprostane (8-isoprostaglandin A(2)), is efficiently conjugated with glutathione by human and rat glutathione transferase A4-4. Chem Res Toxicol 15:1114-1118.
44. Hunot S, Hirsch EC (2003) Neuroinflammatory processes in Parkinson's disease. Ann Neurol 53 Suppl 3:S49-58.
45. Iadecola C, Niwa K, Nogawa S, Zhao X, Nagayama M, Araki E, Morham S, Ross ME (2001) Reduced susceptibility to ischemic brain injury and N-methyl-D-aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice. Proc Natl Acad Sci U S A 98:1294-1299.
46. in t'Veld BA, Ruitenberg A, Hofman A, Launer U, van Duijn CM, Stijnen T, Breteler MM, Stricker BH (2001) Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 345:1515-1521.
47. Iwamoto N, Kobayashi K, Kosaka K (1989) The formation of prostaglandins in the postmortem cerebral cortex of Alzheimer-type dementia patients. J Neurol 236:80-84.
48. Janabi N (2002) Selective inhibition of cyclooxygenase-2 expression by 15-deoxy-Delta(12,14)(12,14)-prostaglandin J(2) in activated human astrocytes, but not in human brain macrophages. J Immunol 168:4747-4755.
49. Kaltschmidt B, Uherek M, Wellmann H, Volk B, Kaltschmidt C (1999) Inhibition of NF-kappaB potentiates amyloid beta-mediated neuronal apoptosis. Proc Natl Acad Sci U S A 96:9409-9414.
50. Kawamoto Y, Nakamura Y, Naito Y, Torii Y, Kumagai T, Osawa T, Ohigashi H, Satoh K, Imagawa M, Uchida K (2000) Cyclopentenone prostaglandins as potential inducers of phase II detoxification enzymes. 15-deoxy-delta(12,14)-prostaglandin j2-induced expression of glutathione S-transferases. J Biol Chem 275:11291-11299.
51. Keelan JA, Sato TA, Marvin KW, Lander J, Gilmour RS, Mitchell MD (1999) 15-Deoxy-Delta(12,14)-prostaglandin J(2), a ligand for peroxisome proliferator-activated receptor-gamma, induces apoptosis in JEG3 choriocarcinoma cells. Biochem Biophys Res Comm 262:579-585.
52. Kikawa Y, Narumiya S, Fukushima M, Wakatsuka H, Hayaishi O (1984) 9-Deoxy-delta 9, delta 12-13,14-dihydroprostaglandin D2, a metabolite of prostaglandin D2 formed in human plasma. Proc Natl Acad Sci U S A 81:1317-1321.
53. Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC, Lehmann JM (1995) A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell 83:813-819.
54. Koizumi T, Negishi M, Ichikawa A (1992) Induction of heme oxygenase by delta 12-prostaglandin J2 in porcine aortic endothelial cells. Prostaglandins 43:121-131.
55. Kondo M, Oya-Ito T, Kumagai T, Osawa T, Uchida K (2001) Cyclopentenone prostaglandins as potential inducers of intracellular oxidative stress. J Biol Chem 276:12076-12083.
56. Kondo M, Shibata T, Kumagai T, Osawa T, Shibata N, Kobayashi M, Sasaki S, Iwata M, Noguchi N, Uchida K (2002) 15-Deoxy-Delta(12,14)-prostaglandin J(2): the endogenous electrophile that induces neuronal apoptosis. Proc Natl Acad Sci U S A 99:7367-7372.
57. Koppal T, Petrova TV, Van Eldik LJ (2000) Cyclopentenone prostaglandin 15-deoxy-Delta(12,14)-prostaglandin J(2) acts as a general inhibitor of inflammatory responses in activated BV-2 microglial cells. Brain Res 867:115-121.
58. Kraft AD, Johnson DA, Johnson JA (2004) Nuclear factor E2-related factor 2-dependent antioxidant response element activation by tert-butylhydroquinone and sulforaphane occurring preferentially in astrocytes conditions neurons against oxidative insult. J Neurosci 24:1101-1112.
59. Kruman I, Bruce-Keller AJ, Bredesen D, Waeg G, Mattson MP (1997) Evidence that 4-hydroxynonenal mediates oxidative stress-induced neuronal apoptosis. J Neurosci 7:5089-5100.
60. Lee JB, Crowshaw K, Takman BH, Attrep KA, Gougoutas JZ (1967) The identification of prostaglandin E2, F2alpha and A2 from rabbit kidney medulla. Biochem J 105:1251-1260.
61. Lee JM, Shih AY, Murphy TH, Johnson JA (2003) NF-E2-related factor-2 mediates neuroprotection against mitochondrial complex I inhibitors and increased concentrations of intracellular calcium in primary cortical neurons. J Biol Chem 278:37948-37956.
62. Lennon AM, Ramauge M, Dessouroux A, Pierre M (2002) MAP kinase cascades are activated in astrocytes and preadipocytes by 15-deoxy-Delta(12-14)- prostaglandin J(2) and the thiazolidinedione ciglitazone through peroxisome proliferator activator receptor gamma-independent mechanisms involving reactive oxygenated species. J Biol Chem 277:29681-29685.
63. Levonen AL, Dickinson DA, Moellering DR, Mulcahy RT, Forman HJ, Darley-Usmar VM (2001) Biphasic effects of 15-deoxy-delta(12,14)-prostaglandin J(2) on glutathione induction and apoptosis in human endothelial cells. Arterioscler Thromb Vasc Biol 21:1846-1851.
64. Levonen AL, Landar A, Ramachandran A, Ceaser EK, Dickinson DA, Zanoni G, Morrow JD, Darley-Usmar VM (2004) Cellular mechanisms of redox cell signaling: role of cysteine modification in controlling antioxidant defenses in response to electrophilic lipid oxidation products. Biochem J 378:373-382.
65. Li L, Tao J, Davaille J, Feral C, Mallat A, Rieusset J, Vidai H, Lotersztajn S (2001) 15-deoxy-Delta 12,14-prostaglandin J2 induces apoptosis of human hepatic myofibroblasts. A pathway involving oxidative stress independently of peroxisome-proliferator-activated receptors. J Biol Chem 276:38152-38158.
66. Li Y, Maher P, Schubert D (1997) A role for 12-lipoxygenase in nerve cell death caused by glutathione depletion. Neuron 19:453-463.
67. Lim SY, Jang JH, Na HK, Lu SC, Rahman I, Surh YJ (2004) 15-Deoxy-Delta12,14-prostaglandin J(2) protects against nitrosative PC12 cell death through up-regulation of intracellular glutathione synthesis. J Biol Chem 279:46263-46270.
68. Liu JD, Lin SY, Ho YS, Pan S, Hung LF, Tsai SH, Lin JK, Liang YC (2003) Involvement of c-jun N-terminal kinase activation in 15-deoxy-delta12,14- prostaglandin J2-and prostaglandin A1-induced apoptosis in AGS gastric epithelial cells. Mol Carcinogenesis 37:16-24.
69. Maggi LB, Jr., Sadeghi H, Weigand C, Scarim AL, Heitmeier MR, Corbett JA (2000) Anti-inflammatory actions of 15-deoxy-delta 12,14-prostaglandin J2 and troglitazone: evidence for heat shock-dependent and -independent inhibition of cytokine-induced inducible nitric oxide synthase expression. Diabetes 49:346-355.
70. Mattson MP, Camandola S (2001) NF-kappaB in neuronal plasticity and neurodegenerative disorders. J Clin Invest 107:247-254.
71. McGeer PL, McGeer EG (1998) Glial cell reactions in neurodegenerative diseases: pathophysiology and therapeutic interventions. Alz Dis Assoc Dis 12 Suppl 2:S1-6.
72. McLaughlin B, Hartnett KA, Erhardt JA, Legos JJ, White RF, Barone FC, Aizenman E (2003) Caspase 3 activation is essential for neuroprotection in preconditioning. Proc Natl Acad Sci U S A 100:715-720.
73. Meffert MK, Baltimore D (2005) Physiological functions for brain NF-kappaB. Trends Neurosci 28:37-43.
74. Milatovic D, Zaja-Milatovic S, Montine KS, Horner PJ, Montine TJ (2003) Pharmacologic suppression of neuronal oxidative damage and dendritic degeneration following direct activation of glial innate immunity in mouse cerebrum. J Neurochem 87:1518-526.
75. Milatovic D, Zhang Y, Olson SJ, Montine KS, Roberts LJ, 2nd, Morrow JD, Montine TJ, Dermody TS, Valyi-Nagy T (2002) Herpes simplex virus type 1 encephalitis is associated with elevated levels of F2-isoprostanes and F4-neuroprostanes. J Neurovirology 8:295-305.
76. Milne GL, Musiek ES, Morrow JD (2005) The cyclopentenone (a(2)/j(2)) isoprostanes-unique, highly reactive products of arachidonate peroxidation. Antioxid Redox Signaling 7:210-220.
77. Milne GL, Zanoni G, Porta A, Sasi S, Vidari G, Musiek ES, Freeman ML, Morrow JD (2004) The cyclopentenone product of lipid peroxidation, 15-A2t-isoprostane, is efficiently metabolized by HepG2 cells via conjugation with glutathione. Chem Res Toxicol 17:17-25.
78. Minghetti L (2004) Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. J Neuropathol Exp Neurol 63:901-910.
79. Minghetti L, Greco A, Cardone F, Puopolo M, Ladogana A, Almonti S, Cunningham C, Perry VH, Pocchiari M, Levi G (2000) Increased brain synthesis of prostaglandin E2 and F2-isoprostane in human and experimental transmissible spongiform encephalopathies. J Neuropath Exp Neurol 59:866-871.
80. Montine TJ, Beal MF, Cudkowicz ME, O'Donnell H, Margolin RA, McFarland L, Bachrach AF, Zackert WE, Roberts LJ, Morrow JD (1999) Increased CSF F2-isoprostane concentration in probable AD. Neurology 52:562-565.
81. Montine TJ, Beal MF, Robertson D, Cudkowicz ME, Biaggioni I, O'Donnell H, Zackert WE, Roberts U, Morrow JD (1999) Cerebrospinal fluid F2-isoprostanes are elevated in Huntington's disease. Neurology 52:1104-1105.
82. 2-isoprostane concentrations in patients with Alzheimer disease, other dementias, and in age-matched controls. Arch Pathol Lab Med 125:510-512.
83. Montine TJ, Markesbery WR, Morrow JD, Roberts LJ, 2nd (1998) Cerebrospinal fluid F2-isoprostane levels are increased in Alzheimer's disease. Ann Neurol 44:410-413.
84. Montine TJ, Milatovic D, Gupta RC, Valyi-Nagy T, Morrow JD, Breyer RM (2002) Neuronal oxidative damage from activated innate immunity is EP2 receptor-dependent. J Neurochem 83:463-470.
85. Montine TJ, Montine KS, Reich EE, Terry ES, Porter NA, Morrow JD (2003) Antioxidants significantly affect the formation of different classes of isoprostanes and neuroprostanes in rat cerebral synaptosomes. Biochem Pharmacol 65:611-617.
86. Montine TJ, Sidell KR, Crews BC, Markesbery WR, Marnett LJ, Roberts LJ, 2nd, Morrow JD (1999) Elevated CSF prostaglandin E2 levels in patients with probable AD. Neurology 53:1495-1498.
87. Moos PJ, Edes K, Fitzpatrick FA (2000) Inactivation of wild-type p53 tumor suppressor by electrophilic prostaglandins. Proc Natl Acad Sci U S A 97:9215-9220.
88. Mori TA, Beilin LJ (2004) Omega-3 fatty acids and inflammation. Curr Atheroscler Rep 6:461-467.
89. Morris MC, Evans DA, Bienias JL, Tangney CC, Bennett DA, Wilson RS, Aggarwal N, Schneider J (2003) Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch Neurol 60:940-946.
90. Morrow JD, Awad JA, Boss HJ, Blair IA, Roberts LJ, 2nd (1992) Non-cyclooxygenase-derived prostanoids (F2-isoprostanes) are formed in situ on phospholipids. Proc Natl Acad Sci USA 89:10721-10725.
91. Morrow JD, Harris TM, Roberts LJ, 2nd (1990) Noncyclooxygenase oxidative formation of a series of novel prostaglandins: analytical ramifications for measurement of eicosanoids (erratum appears in Analyt Biochem 1990 Apr;186(1):184-5). Analyt Biochem 184:1-10.
92. Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, Roberts LJ, 2nd (1990) A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci U S A 87:9383-9387.
93. Morrow JD, Minton TA, Mukundan CR, Campbell MD, Zackert WE, Daniel VC, Badr KF, Blair IA, Roberts LJ, 2nd (1994) Free radical-induced generation of isoprostanes in vivo. Evidence for the formation of D-ring and E-ring isoprostanes. J Biol Chem 269:4317-4326.
94. Morrow JD, Roberts LJ, 2nd (2001) Lipid-Derived Autocoids: Eicosanoids and Platelet Activating Factor. In Goodman & Gilman's The Pharmcological Basis of Therapeutics, Hardman JG, Limbird LE, Gilman AG (eds), 10th Edition, Chapter 26, pp. 669-87, McGraw-Hill: New York
95. Morrow JD, Roberts LJ, 2nd (1999) Mass spectrometric quantification of F2-isoprostanes in biological fluids and tissues as measure of oxidant stress. Meth Enzymol 300:3-12.
96. Morrow JD, Scruggs J, Chen Y, Zackert WE, Roberts LJ, 2nd (1998) Evidence that the E2-isoprostane, 15-E2t-isoprostane (8-iso-prostaglandin E2) is formed in vivo. J Lipid Res 39:1589-1593.
97. Mullally JE, Moos PJ, Edes K, Fitzpatrick FA (2001) Cyclopentenone prostaglandins of the J series inhibit the ubiquitin isopeptidase activity of the proteasome pathway. J Biol Chem 276:30366-30373.
98. Murphy TH, Miyamoto M, Sastre A, Schnaar RL, Coyle JT (1989) Glutamate toxicity in a neuronal cell line involves inhibition of cystine transport leading to oxidative stress. Neuron 2:1547-1558.
99. Narumiya S, Fukushima M (1986) Site and mechanism of growth inhibition by prostaglandins. I. Active transport and intracellular accumulation of cyclopentenone prostaglandins, a reaction leading to growth inhibition. J Pharmacol Exp Ther 239:500-505.
100. Narumiya S, Ohno K, Fukushima M, Fujiwara M (1987) Site and mechanism of growth inhibition by prostaglandins. III. Distribution and binding of prostaglandin A2 and delta 12-prostaglandin J2 in nuclei. J Pharmacol Exp Ther 242:306-311.
101. Nencioni A, Lauber K, Grunebach F, Brugger W, Denzlinger C, Wesselborg S, Brossart P (2002) Cyclopentenone prostaglandins induce caspase activation and apoptosis in dendritic cells by a PPAR-gamma-independent mechanism: regulation by inflammatory and T cell-derived stimuli. Exp Hematology 30:1020-1028.
102. Nogawa S, Zhang F, Ross ME, Iadecola C (1997) Cyclo-oxygenase-2 gene expression in neurons contributes to ischemic brain damage. J Neurosci 17:2746-2755.
103. Ogorochi T, Narumiya S, Mizuno N, Yamashita K, Miyazaki H, Hayaishi O (1984) Regional distribution of prostaglandins D2, E2, and F2 alpha and related enzymes in postmortem human brain. J Neurochem 43:71-82.
104. Oka A, Takashima S (1997) Induction of cyclo-oxygenase 2 in brains of patients with Down's syndrome and dementia of Alzheimer type: specific localization in affected neurones and axons. Neuroreport 8:1161-1164.
105. Ou JJ, Zhang Y, Montine TJ (2002) In vivo assessment of lipid peroxidation products associated with age-related neurodegenerative diseases. Exp Neurol 175:363-369.
106. Pasinetti GM, Aisen PS (1998) Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain. Neuroscience 87:319-324.
107. Paumi CM, Wright M, Townsend AJ, Morrow CS (2003) Multidrug resistance protein (MRP) 1 and MRP3 attenuate cytotoxic and transactivating effects of the cyclopentenone prostaglandin, 15-deoxy-Delta(12,14)prostaglandin J2 in MCF7 breast cancer cells. Biochemistry 42:5429-5437.
108. Pepicelli O, Fedele E, Bonanno G, Raiteri M, Ajmone-Cat MA, Greco A, Levi G, Minghetti L (2002) In vivo activation of N-methyl-D-aspartate receptors in the rat hippocampus increases prostaglandin E(2) extracellular levels and triggers lipid peroxidation through cyclooxygenase-mediated mechanisms. J Neurochem 81:1028-1034.
109. Perez-Sala D, Cernuda-Morollon E, Canada FJ (2003) Molecular basis for the direct inhibition of AP-1 DNA binding by 15-deoxy-Delta 12,14-prostaglandin J2. J Biol Chem 278:51251-51260.
110. Perez-Sala D, Cernuda-Morollon E, Pineda-Molina E, Canada FJ (2002) Contribution of covalent protein modification to the antiinflammatory effects of cyclopentenone prostaglandins. Ann N Y Acad Sci 973:533-536.
111. Petrova TV, Akama KT, Van Eldik LJ (1999) Cyclopentenone prostaglandins suppress activation of microglia: down- regulation of inducible nitric-oxide synthase by 15-deoxy-Delta12,14-prostaglandin 12. Proc Natl Acad Sci U S A 96:4668-4673.
112. Pratico D, Clark CM, Lee VM, Trojanowski JQ, Rokach J, FitzGerald GA (2000) Increased 8,12-iso-iPF2alpha-VI in Alzheimer's disease: correlation of a noninvasive index of lipid peroxidation with disease severity. Ann Neurol 48:809-812.
113. Qin ZH, Wang Y, Chen RW, Wang X, Ren M, Chuang DM, Chase TN (2001) Prostaglandin A(1) protects striatal neurons against excitotoxic injury in rat striatum. J Pharmacol Exp Ther 297:78-87.
114. Ratan RR, Murphy TH, Baraban JM (1994) Oxidative stress induces apoptosis in embryonic cortical neurons. J Neurochem 62:376-379.
115. Reich EE, Markesbery WR, Roberts LJ, 2nd, Swift LL, Morrow JD, Montine TJ (2001) Brain regional quantification of F-ring and D-/E-ring isoprostanes and neuroprostanes in Alzheimer's disease. Am J Pathol 158:293-297.
116. Reich EE, Montine KS, Gross MD, Roberts LJ, 2nd, Swift LL, Morrow JD, Montine TJ (2001) Interactions between apolipoprotein E gene and dietary alpha-tocopherol influence cerebral oxidative damage in aged mice. J Neurosci 21:S993-S999.
117. Reich EE, Zackert WE, Brame CJ, Chen Y, Roberts LJ, 2nd, Hachey DL, Montine TJ, Morrow JD (2000) Formation of novel D-ring and E-ring isoprostane-like compounds (D4/E4- neuroprostanes) in vivo from docosahexaenoic acid. Biochemistry 39:2376-2383.
118. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK (1998) The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391:79-82.
119. Roberts LJ, 2nd, Montine TJ, Markesbery WR, Tapper AR, Hardy P, Chemtob S, Dettbarn WD, Morrow JD (1998) Formation of isoprostane-like compounds (neuroprostanes) in vivo from docosahexaenoic acid. J Biol Chem 273:13605-13612.
120. Rohn TT, Wong SM, Cotman CW, Cribbs DH (2001) 15-deoxy-delta 12,14-prostaglandin J2, a specific ligand for peroxisome proliferator-activated receptor gamma, induces neuronal apoptosis. Neuroreport 12:839-843.
121. Rossi A, Kapahi P, Natoli G, Takahashi T, Chen Y, Karin M, Santoro MG (2000) Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase. Nature 403:103-108.
122. Rovin BH, Lu L, Cosio A (2001) Cyclopentenone prostaglandins inhibit cytokine-induced NF-κB activation and chemokine production by human mesangial cells. J Amer Soc Nephrol 12:1659-1667.
123. Sairanen T, Ristimaki A, Karjalainen-Lindsberg ML, Paetau A, Kaste M, Lindsberg PJ (1998) Cyclooxygenase-2 is induced globally in infarcted human brain. Ann Neurol 43:738-747.
124. Skinner ER, Watt C, Besson JA, Best PV (1993) Differences in the fatty acid composition of the grey and white matter of different regions of the brains of patients with Alzheimer's disease and control subjects. Brain 116:717-725.
125. Smith SA, Monteith GR, Holman NA, Robinson JA, May FJ, Roberts-Thomson SJ (2003) Effects of peroxisome proliferator-activated receptor gamma ligands ciglitazone and 15-deoxy-delta 12,14-prostaglandin J2 on rat cultured cerebellar granule neuronal viability. J Neuroscience Res 72:747-755.
126. Stanciu M, Wang Y, Kentor R, Burke N, Watkins S, Kress G, Reynolds I, Klann E, Angiolieri MR, Johnson JW, DeFranco DB (2000) Persistent activation of ERK contributes to glutamate-induced oxidative toxicity in a neuronal cell line and primary cortical neuron cultures. J Biol Chem 275:12200-12206.
127. Stewart WF, Kawas C, Corrada M, Metter EJ (1997) Risk of Alzheimer's disease and duration of NSAID use. Neurology 48:626-632.
128. Straus DS, Glass CK (2001) Cyclopentenone prostaglandins: new insights on biological activities and cellular targets. Med Res Rev 21:185-210.
129. Straus DS, Pascual G, Li M, Welch JS, Ricote M, Hsiang CH, Sengchanthalangsy LL, Ghosh G, Glass CK (2000) 15-deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF- kap pa B signaling pathway. Proc Natl Acad Sci U S A 97:4844-4849.
130. Tan S, Sagara Y, Liu Y, Maher P, Schubert D (1998) The regulation of reactive oxygen species production during programmed cell death. J Cell Biol 141:1423-1432.
131. Teismann R Ferger B (2001) Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease. Synapse 39:167-174.
132. Teismann P, Tieu K, Choi DK, Wu DC, Naini A, Hunot S, Vila M, Jackson-Lewis V, Przedborski S (2003) Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc Natl Acad Sci U S A 100:5473-5478.
133. van Iersel ML, Cnubben NH, Smink N, Koeman JH, van Bladeren PJ (1999) Interactions of prostaglandin A2 with the glutathione-mediated biotransformation system. Biochem Pharmacol 57:1383-1390.
134. Wang X, Qin ZH, Leng Y, Wang Y, Jin X, Chase TN, Bennett MC (2002) Prostaglandin A1 inhibits rotenone-induced apoptosis in SH-SYSY cells. J Neurochem 83:1094-1102.
135. Wang X, Zhao X, Mao ZY, Wang XM, Liu ZL (2003) Neuroprotective effect of docosahexaenoic acid on glutamate-induced cytotoxicity in rat hippocampal cultures. Neuroreport 14:2457-2461.
136. Willoughby DA, Moore AR, Colville-Nash PR (2000) Cyclopentenone prostaglandins-new allies in the war on inflammation. Nat Med 6:137-138.
137. Yasojima K, Tourtellotte WW, McGeer EG, McGeer PL (2001) Marked increase in cyclooxygenase-2 in ALS spinal cord: implications for therapy. Neurology 57:952-956.
138. Yokoyama Y, Saito M, Saito T, Yuguchi T, Sawataishi M, Sakamoto T, Tazawa K, Tsukada K (2000) Synergistic antiproliferative effect of delta 12-prostaglandin J2 (delta 12-PGJ2) and hyperthermia on human esophageal cancer cell lines. Hum Cell 13:23-33.
139. Zandi PP, Anthony JC, Hayden KM, Mehta K, Mayer L, Breitner JC (2002) Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County Study. Neurology 59:880-886.
140. Zanoni G, Porta A, Castronovo F, Vidari G (2003) First total synthesis of J(2) isoprostane. J Organic Chem 68:6005-6010.
141. Zanoni G, Porta A, Vidari G (2002) First total synthesis of A(2) isoprostane. J Org Chem 67:4346-4351.
142. Zusman RM, Caldwell BV, Speroff L, Behrman HR (1972) Radioimmunoassay of the A prostaglandins. Prostaglandins 2:41-53.